Biovitrum gains access to Affibody technology

Pharma company Biovitrum has signed a collaboration agreement with Swedish biotech Affibody with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases.

The agreement gives Biovitrum access to the proprietary technology platforms of Affibody molecules, as well as the unique albumin-binding technology for pharmaceutical development. It consists of a defined protein target development collaboration and a product licence agreement.

Affibody molecules are small stable proteins that can have the same effects as large proteins, but also offer potential efficacy, safety, administration route and price benefits. The albumin-binding technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life.

"This innovative technology is a strong addition to Biovitrum's biopharmaceuticals and process capabilities," said Peter Edman, cso of Biovitrum. "Moreover, the collaboration fits perfectly with our specialist indication focus and strategy."

"This collaboration with Biovitrum represents an important step in Affibody's efforts to become profitable within the coming two years," added David Bejker, president and ceo of Affibody. "It is the first collaboration with our novel biopharmaceutical concept, based on the second generation Affibody molecules and the second generation of our albumin binding technology.

"We believe that Biovitrum is an ideal partner for the development and commercialisation of products based on our technology platforms."